Korean J Schizophr Res.
2021 Apr;24(1):1-7. 10.16946/kjsr.2021.24.1.1.
Current Status of Clozapine for Treatment-Resistant Schizophrenia
- Affiliations
-
- 1Department of Psychiatry, Seoul National University Hospital, Seoul, Korea
- KMID: 2515675
- DOI: http://doi.org/10.16946/kjsr.2021.24.1.1
Abstract
- Clozapine is the first and most effective atypical antipsychotic drug for treatment-resistant schizophrenia (TRS). After withdrawal of clozapine due to concerns of agranulocytosis, clozapine was reintroduced with a comprehensive safety monitoring system, the clozapine patient monitoring system (CPMS). The reintroduction was a response to the pressure from psychiatrists and patients with TRS and their families. Clozapine is still the best single agent for the treatment of TRS. However, approximately 30% of patients with TRS still show psychotic symptoms. In patients with clozapine-resistant schizophrenia (CRS), augmentation of other antipsychotic agents could be considered after a thorough evaluation of proper clozapine treatment. In this review, the status of clozapine in patients with TRS and CRS will be discussed.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Efficacy and Safety of Concurrent Administration of Clozapine and Electroconvulsive Therapy: A Case Report
- Clozapine in the Time of COVID-19
- Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome
- Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
- Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report
